Hiroaki SATOH, Shijima TAGUCHI, Hajime OSAWA, Katsunori KAGOHASHI, Shinichiro OKAUCHI

Immuno-checkpoint inhibitor-associated hyper-eosinophilia and tumor shrinkage

PDF

___

Helbig G. Advances in the diagnosis and treatment of eosinophilia. Curr Opin Hematol 2014;21:3-7.
Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-79.
Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitorassociated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res 2017;27:271-3.
Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, Matsumoto S, et al. Nivolumab-induced hypophysis in a patient with advanced malignant melanoma. Endocarp J 2016;63:905-12.
Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Kyama J, Saiki M, et al. Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy. Anticancer Res 2017;37:4229-32.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16: 257-65.
Bertrand A, Kestin M, Barnetche T, Truhitte ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and metaanalysis. BMC medicine 2015;13:211.
Chen TW, Raze AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncor. 2015;26:1824-9.
Gao J, He Q, Subudhi S, Aparicio A, Serita-Saavedra A, Lee DH, et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 2015;34:5411-7.
Horvat TZ, Adel NG, Dang TO, Woo K, Pangaea’s K, Mommas P, et al. Immune related adverse events (eras) and overall survival (OS) in patients (pts) with melanoma (meld) treated outside of a clinical trial with ipilimumab (pie) at Memorial Slogan Kettering (MSK). Pigment Cell and Melanoma Research 2014;27;1169:1200.
Johnson DB, Friedman DL, Berry EG, Decker I, Ye F, Zhao S, et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res 2015.
Korman NJ, Woods SG. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol 1995;133:967-71.
Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130:607-12.
Sohn KH, Song WJ, Kim BK, Kang MK, Lee SY, Suh JW, et al. Eosinophilic myocarditis: case series and literature review. Asia Pacific Allergy 2015;5:123-7.